Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-finding study of GSK4532990 in alcohol-related liver disease
jRCT2061240059Phase 2Recruiting
- Sponsor
- GSK
- Start
- Nov 2024
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
01
Overview
Phase 2, randomised, double-blind trial of GSK4532990 in alcoholic liver disease (ALD) and steatohepatitis (5 arms), sponsored by GSK. Primary endpoints: Number of participants with adverse events and serious adverse events, Number of participants with potentially clinically relevant changes in ECG, vital signs, and clinical laboratory tests and 2 more. Started Nov 2024; status: recruiting.
02
Drugs
GSK4532990
03
Conditions
alcoholic liver disease (ALD)steatohepatitis
Beyond the preview
Go deeper on jRCT2061240059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240059.